The total return over the past 12 months is -12.19% vs. +16.94% for the S&P 500. So far it's up -38.95% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (12.19%) | +9.33% | +1.64% | (16.41%) | N/A | N/A |
| Total Return CAGR | (12.19%) | +9.33% | +1.64% | (16.41%) | N/A | N/A |
| Revenue CAGR | N/A | +264.29% | +93.92% | +37.95% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Viridian Therapeutics, Inc. (VRDN)
| Year | Start price | End price | VRDN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $31.12 | $19.00 | (38.95%) | +14.51% | (53.46%) |
| 2025 | $19.17 | $31.12 | +62.34% | +17.72% | +44.62% |
| 2024 | $21.78 | $19.17 | (11.98%) | +24.89% | (36.87%) |
| 2023 | $29.21 | $21.78 | (25.44%) | +26.19% | (51.63%) |
| 2022 | $19.77 | $29.21 | +47.75% | (18.17%) | +65.92% |
| 2021 | $16.45 | $19.77 | +20.18% | +28.74% | (8.56%) |
| 2020 | $7.20 | $16.45 | +128.47% | +18.37% | +110.10% |
| 2019 | $45.45 | $7.20 | (84.16%) | +31.22% | (115.38%) |
| 2018 | $156.45 | $45.45 | (70.95%) | (4.56%) | (66.39%) |
| 2017 | $75.15 | $156.45 | +108.18% | +21.70% | +86.48% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
